As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider?

Ben McPoland takes a look at the largest UK stock by market cap to assess whether it might be overvalued after a very strong run.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) is a UK stock on fine form. It recently notched a 52-week high of 13,290p not long after the pharmaceutical giant hit the milestone of becoming the FTSE 100‘s first £200bn company.

Over five years, it’s up around 81%, demolishing the Footsie’s return. Across a decade, it’s almost trebled, leaving underwhelming peer GSK in the dust.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL31 Aug 201931 Aug 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

I find this impressive considering the company isn’t playing in the high-growth GLP-1 weight-loss sandbox (at least not yet). Plus, unlike Covid vaccine peers Moderna and Pfizer, it’s managed to navigate and overcome the post-pandemic slump in vaccine sales.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

But this relentless rise higher has also made the share more expensive. Does it still offer any value today? Let’s take a look.

Taking stock

AstraZeneca trades on a forward price-to-earnings (P/E) ratio of 21. Is that expensive? Well, compared to the FTSE 100 (around 12) and GSK (10.3), it most certainly is.

But the company is truly global and looks cheap versus the forward P/E multiples of Novo Nordisk (39.7) and Eli Lilly (57.8). That said, those stocks are arguably a bit frothy right now due to investor excitement around the GLP-1 boom. Merck is trading on a forward P/E of 19.7.

Based on this metric, I’d say the stock is fairly valued. It broadly aligns with large healthcare firms in the S&P 500.

The dividend yield is also often used by investors to compare the attractiveness of different stocks. On this front, AstraZeneca doesn’t offer tasty income prospects, with a pretty low dividend yield of 1.8%.

Created at TradingView

Oncology pioneer

In H1, total revenue increased 18% year on year to $25.6bn. Double-digit growth was recorded across all four of its divisions.

  • Oncology: up 22%
  • Cardiovascular, Renal & Metabolism: 22%
  • Respiratory & Immunology: 22%
  • Rare Disease: 15%

AstraZeneca’s ambition is to transform cancer treatment for patients by replacing chemotherapy and radiotherapy with more targeted treatments.

In line with this, it recently acquired cancer company Fusion Pharma, which specialises in radioconjugates (a more precise mechanism of cancer cell killing compared with traditional radiation therapy).

Additionally, it aims to enter the lucrative global obesity market. It has licenced Eccogene’s ECC5004, a once-daily weight management pill that the company believes could ultimately prove more popular than the current once-weekly injections (including Wegovy).

Of course, there’s a possibility these disruptive new treatments don’t work out. Meanwhile, the firm is exposed to regulatory risk and the high probability of some late-stage clinical trial failures.

My Foolish takeaway

AstraZeneca has grown its revenue rapidly in recent years, from $25bn in 2020 to $46bn in 2023.

Created at TradingView

By 2030, it’s aiming for $80bn in annual revenue. This will be driven by the expected launch of 20 new medicines, many with the potential to generate $5bn+ in peak annual sales.

CEO Pascal Soriot has called this a “new era of growth”. This is no slow-moving pharma giant.

Assuming the same profit margin is maintained, its earnings could exceed $10bn by then, up from just under $6bn in 2023.

This is why I became a shareholder earlier this year. But if I didn’t already own the stock, I’d still consider buying it today to hold for at least the next five years.

But there are other promising opportunities in the stock market right now. In fact, here are:

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc and Moderna. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 FTSE 100 shares that could make it rain dividends in 2025

Ben McPoland considers a trio of high-yield FTSE dividend stocks that are set to offer very attractive passive income this…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

On a P/E ratio of 6, is the Centrica share price a bargain?

The Centrica price-to-earnings ratio is in the mid-single digits. This writer weighs some pros and cons of adding the share…

Read more »

Investing Articles

2 top growth stocks to consider for 2025!

These growth stocks are expected to deliver more spectacular earnings increases in 2025. Is it time to consider loading up?

Read more »

Stack of one pound coins falling over
Investing Articles

Can this 10.8% yield from a FTSE 250 share last?

A well-known FTSE 250 share now has a dividend yield not far off 11%. Our writer digs into the business…

Read more »

Investing Articles

How to use a £20k ISA allowance to invest for passive income

The idea of enjoying some passive income in our old age can definitely be a realistic ambition, depending on how…

Read more »

Investing Articles

Down 95%, could the THG share price bounce back in 2025?

The THG share price has tanked in the past year -- and before, too. So will our writer buy in…

Read more »

US Stock

Prediction: AI stocks will outperform again in 2025 and Nvidia will hit $200

Over the last two years, Nvidia stock has soared on the back of AI. Ed Sheldon believes the stock, and…

Read more »

Elevated view over city of London skyline
Investing Articles

10.9%+ yield! Here’s my 2025-2027 M&G dividend forecast

Christopher Ruane explains why, although the M&G dividend yield already tops 10%, he's hopeful it could move even higher over…

Read more »